2025 HCPCS Code Q0181
Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
TAGS: therapeutic dosage exceed complete substitute chemotherapy approved regimen prescription unspecified| Short Description | Unspecified oral anti-emetic |
| HCPCS Action Code | N - No maintenance for this code |
| HCPCS Coverage Code | D - Special coverage instructions apply |
| HCPCS Code Added Date | April 01, 1998 |
| HCPCS Action Effective Date | April 01, 1998 |
| HCPCS Pricing Indicator Code | 51 - Drugs |
| HCPCS Type Of Service Code | 1 - Medical care |
| HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
| HCPCS Anesthesia Base Unit Quantity | 0 |
| HCPCS Coverage Issues Manual Reference Section Number |
Check Similar HCPCS Codes
- Q0173 - Trimethobenzamide hcl 250mg
- Q0174 - Thiethylperazine maleate10mg
- Q0175 - Perphenazine 4mg oral
- Q0177 - Hydroxyzine pamoate 25mg
- Q0180 - Dolasetron mesylate oral
- Q0181 - Unspecified oral anti-emetic
- Q0220 - Tixagev and cilgav, 300mg
- Q0221 - Tixagev and cilgav, 600mg
- Q0222 - Bebtelovimab 175 mg
- Q0224 - Inj, pemivibart, 4500 mg
- Q0235 - Inj, monoclon antibody, 1 mg
- Q0237 - Inj, tocilizumab-anoh, hospi
- Q0239 - Bamlanivimab-xxxx
- Q0240 - Casirivi and imdevi 600 mg
- Q0243 - Casirivimab and imdevimab
- Q0244 - Casirivi and imdevi 1200 mg
- Q0245 - Bamlanivimab and etesevima
- Q0247 - Sotrovimab
- Q0249 - Tocilizumab for covid-19
- Q0477 - Pwr module pt cable lvad rpl
